Market Overview

UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

Share:
Related NPSP
3 Niche ETFs Breaking Out
Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results

In a report published Wednesday, Jefferies analyst Eun K. Yang downgraded the rating on NPS Pharmaceuticals (NASDAQ: NPSP) from Buy to Hold, but reiterated the $38.00 price target.

In the report, Jefferies noted, “FY14 guidance/4Q13 sales of Gattex preannounced on 1/8/14. Solid Gattex U.S. launch in 2013 and anticipation of bigger Natpara opportunity resulted in strong stock performance. Now trading at ~17.2x EV/'14 revenue (vs. ~16.1x for BMRN and ~17.5x for ALXN), we view near term, potential of Gattex/Revestive and Natpara is largely priced in. Thus, we downgrade NPSP to Hold on valuation and maintain $38 PT.”

NPS Pharmaceuticals closed on Tuesday at $37.95.

Latest Ratings for NPSP

DateFirmActionFromTo
Jan 2015JP MorganMaintainsNeutral
Jan 2015BarclaysDowngradesOverweightEqual-weight
Jan 2015Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for NPSP
View the Latest Analyst Ratings

Posted-In: Eun K. Yang JefferiesAnalyst Color Downgrades Analyst Ratings

 

Related Articles (NPSP)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→